We have revised our model following a soft 1Q25 performance in Radiology Solutions, contrasted by continued strong momentum in Agfa's HealthCare IT division—fuelled by growing customer adoption of its cloud-based technologies. While the Digital Printing Solutions equipment segment faced headwinds from ongoing economic uncertainty, and demand for Agfa's Zirfon membranes for green hydrogen production slowed in Europe and North America, the company maintains a positive long-term outlook for both bu...
WDP has invested €30m its food logistics portfolio. The acquisition includes five urban distribution sites across Belgium. These sites total 25k sqm of lettable area on 75k sqm of land. The properties are fully leased on long-term triple-net agreements. Four sites are leased to Sligro, and one to Horeca Van Zon. The acquisition was completed via a contribution in kind of 1,468,380 new shares at €20.43 per share, a 5% discount. This move strengthens WDP's partnership with Sligro in the Benelux. ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Warehouses de Pauw NV/SA (WDP or the company) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 5 June 2025 in which we reassessed the appropriateness of the...
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
Hyloris announced that its partner Avenacy received FDA approval for its ANDA (generic NDA) of Tranexamic Acid Intravenous Premix Ready-to-Use (RTU), with launch planned for 2H25. This product, approved through the generic ANDA pathway, is non-core for the company, as Hyloris' main focus is on the more valuable reformulation and repurposing 505(b)(2) pathway. Sales of intravenous tranexamic acid reached $ 29.1m in the 12 months up to March 2025, and we estimate Hyloris could receive approx. $ 2m...
Hyloris announced an exclusive licensing agreement with AFT Pharmaceuticals for XTRAZA (tranexamic acid oral rinse) in Canada, Australia, New Zealand, Singapore and Hong Kong. Under the terms of the agreement Hyloris will receive up to 50% of the gross profits generated. This deal with AFT follows a previously announced agreement for the UK with Colonis Pharma. A phase 3 trial for XTRAZA is ongoing in the US and EU, with data expected by YE25, and we note that a deal for XTRAZA in the larger US...
VGP Announces €76 Million Tap Issuance Under Green Bond Framework with EBRD PRESS RELEASE Regulated Information NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SEC...
VGP Kondigt € 76 Miljoen Tap-uitgifte Aan Onder Green Bond-Raamwerk met EBRD PERSBERICHT Gereguleerde Informatie NIET VOOR VRIJGAVE, PUBLICATIE OF VERSPREIDING IN OF NAAR OF AAN ENIGE PERSOON GEVESTIGD OF WOONACHTIG IN DE VERENIGDE STATEN VAN AMERIKA, DIENS TERRITORIA EN BEZITTINGEN (INCLUSIEF PUERTO RICO, DE AMERIKAANSE MAAGDENEILANDEN, GUAM, AMERIKAANS SAMOA, HET EILAND WAKE EN DE NOORDELIJKE MARIANA EILANDEN), ENIGE STAAT VAN DE VERENIGDE STATEN VAN AMERIKA OF HET DISTRICT VAN COLUMBIA (DE “VERENIGDE STATEN”) OF AAN ENIGE AMERIKAANSE PERSOON (U.S. PERSON, ZOALS GEDEFINIEERD IN REGULATI...
In this note, we review the pipeline and rental model in light of the current tariff uncertainty. We believe that VGP is not well understood in the market due to the complexity of its JV structure. VGP is a hybrid developer/investor that gradually shifts more to the latter. We model the financials on a look-through basis and value the consolidated cash flows including JV's. VGP understands the skill of leveraging its permitted landbank into yielding assets. The investments are largely recycled t...
1Q25 was marked by a weak performance in Radiology Solutions (1Q is traditionally a seasonally weak quarter but now with strong impact of the decline of the medical film markets, particularly in China) and the continued strong performance of Agfa's HealthCare IT division, driven by customer adoption of Agfa's cloud technology. While Agfa's Digital Printing Solutions equipment business faced challenges due to economic uncertainty, and the market for Agfa's Zirfon membranes for green hydrogen prod...
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Regulated information May 14, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Group performance: continued success of the strategic transformation Improved sales mix between growth engines and mature businesses and good cost control compensated for the negative impact of the market ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.